Vertex Pharmaceuticals Inc. (VRTX) announced that the European Commission has approved expansion of the indication for KALYDECO (ivacaftor) to include children ages 2 to 5 with cystic fibrosis who have one of nine gating mutations in the cystic fibrosis transmembrane conductance regulator gene and to include people with CF ages 18 and older who have an R117H mutation.
Ivacaftor was previously approved in the European Union for use in people with CF ages 6 and older who have one of nine gating mutations.
For comments and feedback contact: editorial@rttnews.com
Business News